CompanyNasdaqPetach Tikva, L3

PolyPid Ltd

PolyPid develops long-acting, controlled-release drugs for surgical care and metabolic diseases.

SEC EDGAR ClinicalTrials.gov

6-KOct 1Latest SEC filing

Form DJun 23$27M sold

October 2026

EMA validates PolyPid's marketing application for D-PLEX100

Oct 1Regulatory decisionPolyPid Ltd

August 2026

PolyPid reports Q2 2026 results, FDA priority review for D-PLEX100

Aug 12Regulatory milestonePolyPid Ltd

July 2026

PolyPid's D-PLEX100 NDA accepted with priority review, PDUFA date set for November 2026

Jul 29Regulatory milestonePolyPid Ltd

PolyPid partners with Azurity to commercialize D-PLEX100 in U.S. and Canada

Jul 21PartnershipPolyPid Ltd